安永料香港上半年IPO集資額達2,108億元 創十年新高
安永發表新股市場中期回顧及展望,預期今年上半年香港首次公開發售(IPO)宗數下降,按年跌24%至45宗,集資額則增長127%至2,108億元,創2010年以來同期十年新高。
安永亞太區上市服務主管蔡偉榮表示,上半年全球新股市場活躍,IPO宗數增長148%至1,020宗,合計集資2,106億美元,按年增長近2倍。納斯達克交易所暫時以集資額461億美元排名首位,紐約交易所排名第二,達289億美元,而香港則排第三位,與去年同期持平。
安永會計師事務所審計服務合伙人賴耘(峰)指,受惠於新股上市制度改革,近年香港引入不少未錄收入生物科技公司、同股不同權企業及中概股第二上市,今年上半年有65%集資額來自相關IPO。
蔡偉榮表示,生物科技企業活躍於香港市場,當中不乏反應理想的IPO,預期生科企來港上市的潮流於未來一至兩年將仍然活躍。但他提醒,若有公司持續未能錄得盈利、甚至研發失敗或倒閉,將對市場造成較大衝擊。(gc/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.